GlassScriptPhysician profile
Daniel M Metzger
NPI 1265478192
$4,035.32
in general payments reported to CMS, 2019-2025
36 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $126 · 2021: $503 · 2022: $829 · 2023: $822 · 2024: $694 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $598.09 | 2021-2025 | |
| Glaxosmithkline, LLC. | $467.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $358.21 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.13 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $238.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $235.86 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $195.23 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Lilly USA, LLC | $186.10 | 2021-2024 | Jardiance, Emgality, Zepbound |
| Astellas Pharma US INC | $172.88 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $156.83 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $127.31 | 2022-2024 | |
| Mylan Specialty L.P. | $107.39 | 2019-2024 | Yupelri |
| Dexcom, INC. | $89.23 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $68.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $67.18 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.52 | 2022-2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $60.83 | 2019-2020 | |
| Pfizer INC. | $56.32 | 2019-2024 | |
| Neos Therapeutics, LP | $54.29 | 2019 | |
| Corium, LLC | $50.13 | 2024-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $40.04 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $36.93 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $36.32 | 2020-2023 | Rexulti |
| Tris Pharma INC | $32.26 | 2019-2020 | |
| Lundbeck LLC | $31.37 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $29.16 | 2022 | |
| Abbott Laboratories | $28.60 | 2021-2022 | |
| Shire North American Group INC | $26.75 | 2019 | |
| Exact Sciences Corporation | $19.38 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $18.46 | 2025 | Qelbree |
| Allergan, INC. | $17.22 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $17.08 | 2023 | Opsumit, Uptravi |
| Neurocrine Biosciences, INC. | $17.07 | 2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $16.25 | 2024 | Voquezna |
| Biogen, INC. | $15.23 | 2019 | |
| Amarin Pharma, INC. | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Metzger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.